These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169 [TBL] [Abstract][Full Text] [Related]
3. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Miller JS; Verfaillie C; McGlave P Blood; 1992 Nov; 80(9):2182-7. PubMed ID: 1384796 [TBL] [Abstract][Full Text] [Related]
4. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508 [TBL] [Abstract][Full Text] [Related]
5. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Verfaillie C; Miller W; Kay N; McGlave P Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805 [TBL] [Abstract][Full Text] [Related]
6. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. Lotzová E; Savary CA; Champlin RE J Immunol; 1993 Jun; 150(12):5263-9. PubMed ID: 7685792 [TBL] [Abstract][Full Text] [Related]
7. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. Verfaillie C; Blakolmer K; McGlave P J Exp Med; 1990 Aug; 172(2):509-2. PubMed ID: 2373991 [TBL] [Abstract][Full Text] [Related]
8. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934 [TBL] [Abstract][Full Text] [Related]
9. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848 [TBL] [Abstract][Full Text] [Related]
10. T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors. Bhatia R; McGlave PB Leukemia; 1995 Jun; 9(6):1006-12. PubMed ID: 7596165 [TBL] [Abstract][Full Text] [Related]
11. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Pierson BA; Miller JS Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949 [TBL] [Abstract][Full Text] [Related]
12. A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. Bhatia R; McGlave PB; Miller JS; Wissink S; Lin WN; Verfaillie CM Exp Hematol; 1997 Aug; 25(9):980-91. PubMed ID: 9257812 [TBL] [Abstract][Full Text] [Related]
13. CD14+ peripheral blood mononuclear cells from chronic myeloid leukemia and normal donors are inhibitory to short- and long-term cultured colony-forming cells. Heissig B; Pasternak G; Hörner S; Schwerdtfeger R; Rossol S; Hehlmann R Leuk Res; 2000 Mar; 24(3):217-31. PubMed ID: 10739004 [TBL] [Abstract][Full Text] [Related]
15. Ex vivo culture of CD34+/Lin-/DR- cells in stroma-derived soluble factors, interleukin-3, and macrophage inflammatory protein-1alpha maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay. Miller JS; McCullar V; Verfaillie CM Blood; 1998 Jun; 91(12):4516-22. PubMed ID: 9616147 [TBL] [Abstract][Full Text] [Related]
16. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Lundell BI; McCarthy JB; Kovach NL; Verfaillie CM Leukemia; 1997 Jun; 11(6):822-9. PubMed ID: 9177435 [TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Bhatia R; McCarthy JB; Verfaillie CM Blood; 1996 May; 87(9):3883-91. PubMed ID: 8611716 [TBL] [Abstract][Full Text] [Related]
18. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Bhatia R; McGlave PB; Dewald GW; Blazar BR; Verfaillie CM Blood; 1995 Jun; 85(12):3636-45. PubMed ID: 7780147 [TBL] [Abstract][Full Text] [Related]
19. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Verfaillie CM Blood; 1993 Oct; 82(7):2045-53. PubMed ID: 7691246 [TBL] [Abstract][Full Text] [Related]
20. CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3--supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells. Verfaillie CM; Miller JS Blood; 1994 Sep; 84(5):1442-9. PubMed ID: 7520771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]